QIAGEN expands Point of Need portfolio with unique AmniSureassay to detect rupture of fetal membranes (ROM) – checked in up to 30% of U.S. pregnancies
Novel FDA-cleared test is highly synergistic with QIAGEN’s clinical sales channels
QIAGEN N.V. QGEN -1.92% (frankfurt prime standard:QIA) today announced the acquisition of AmniSure International LLC, a privately owned Boston company that markets the AmniSure assay for determining whether a pregnant woman is suffering rupture of fetal membranes (ROM), a condition in which fluid leaks from the amniotic sac prematurely.
To read the full, original article click on this link: QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio – MarketWatch
{iframe}http://www.marketwatch.com/story/qiagen-acquires-amnisure-international-to-add-unique-assay-to-emerging-point-of-need-portfolio-2012-05-03{/iframe}